$BDX

BD (Becton, Dickinson and Company) has launched the Liverty TIPS Stent Graft in the U.S. The product is designed for portal hypertension and is supported by interim data from a 177-patient study.

Becton, Dickinson and Company (BDX) shares rose 25.5% in six months, outpacing its industry. The rally is attributed to portfolio realignment, growth in high-margin businesses, and product innovation. BDX expects 2.5% EPS growth for Q4 despite a 13% sales decline. The company raised its full-year EPS guidance and increased shareholder returns. Upcoming results are scheduled for Nov. 5, with an Earnings ESP of 0.21%.

Boston Scientific (BSX) lowered its 2026 revenue growth forecast to 6.0% from 7.8%, citing market slowdowns and a cyberattack. Becton Dickinson (BDX) raised its 2026 adjusted EPS forecast but expects low single-digit revenue growth in 2027. BSX trades at 18.0x earnings, while BDX trades at 55.7x. BSX has higher margins and lower debt but faces margin pressure. BDX offers a 2.2% dividend yield.

Becton, Dickinson and Company (BDX) reported Q3 2026 revenue growth of 5.4% to $4.98B and raised its full-year EPS guidance to $12.67. The company offers a 2.4% yield and has a forward P/E of 13.72x, lower than peers like Medtronic and Stryker. BDX is a Dividend King with 54 years of consecutive dividend growth, and its payout ratio is around 33%. However, risks include potential litigation and restructuring costs.

Solventum (NYSE:SOLV) reported Q2 revenue of $2.21B, up 2.2% YoY, beating estimates. STERIS (NYSE:STE) reported $1.49B, up 7.3% YoY, in line with expectations. BD (NYSE:BDX) reported $4.98B, up 5.4% YoY, beating estimates. CONMED (NYSE:CNMD) reported $343.5M, flat YoY, beating estimates. Stocks reacted accordingly.

BD (NYSE: BDX) reported positive nine-month results from the AGILITY trial for its Revello™ Vascular Covered Stent, showing high vessel patency and low reintervention rates in treating iliac artery disease. The study met its primary endpoint with a 2.8% failure rate, and patients showed improved mobility and symptoms. The trial is ongoing, with follow-up through 36 months. The device is CE marked but remains investigational in the U.S.

Becton Dickinson agreed to invest $19 billion in the U.S. over several years, including $3 billion for expanding domestic manufacturing, in exchange for future tariff relief. The company plans to increase U.S. production of medical consumables and needles, aiming for 80% domestic supply. President Trump announced medical device tariffs by year-end. The financial impact of the deal is not yet quantified.

Global healthcare companies, including Pfizer, Eli Lilly, and AstraZeneca, are investing billions in US manufacturing and research. Pfizer plans $70B, Eli Lilly $27B, and AstraZeneca $50B. Investments aim to mitigate supply-chain risks and tariff impacts, with some companies reporting minimal 2025 tariff effects.

BD (BDX) appointed Ferass Abuzaina as worldwide president of its Surgery business unit, effective immediately. He will oversee global strategy, operations, and commercial performance, reporting to Peter Menziuso. Abuzaina joined BD in 2013 and has held various leadership roles.

BD (NYSE: BDX) and the U.S. Government announced a partnership to expand domestic manufacturing of essential medical consumables. BD plans to invest $19 billion in the U.S., including $3 billion for manufacturing expansion, and aims to increase domestic production by 5 billion units annually. The agreement also provides tariff relief for covered products, subject to future actions and milestones.